Managed Healthcare Executive June 13, 2025
In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, talks about the factors that are impacting the biosimilar market.
Healthcare payers now have greater confidence in biosimilars and their ability to provide savings for plans and patients, James D. Chambers, Ph.D., M.Pharm., M.Sc., said in a recent interview. Chambers, who is a health economist at Tufts Medical Center and leads the Specialty Drug Evidence and Coverage (SPEC) Database, said health plans are more eager for biosimilars.
“They know it’s a good negotiating tool and increases options for patients and providers, and they are embracing biosimilars faster,” he said.
It’s been 10 years since the first biosimilar was approved by the FDA: Zarxio (filgrastim-sndz), which references Neupogen and is...
Today's Sponsors
Today's Sponsor